http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
-
Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
-
Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019
-
Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019
-
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal
-
Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal
-
Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights
-
Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights
-
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
-
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
-
Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights
-
Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights
-
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019
-
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019
-
Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE
-
Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE
-
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco
-
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco
-
Optinose Announces License Agreement
-
Optinose Announces License Agreement
-
Sosei Heptares Announces Medicxi to Invest Up To €40 Million in New Collaboration Based on its Orexin Agonist Program
-
OptiNose (OPTN) Reports Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
-
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
-
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
-
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis
-
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis
-
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
-
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
-
Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018
-
Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018
-
Optinose to Highlight Data at Two Upcoming Scientific Meetings
-
Optinose to Highlight Data at Two Upcoming Scientific Meetings
-
Optinose to Present at the 2018 Cantor Global Healthcare Conference
-
Optinose to Present at the 2018 Cantor Global Healthcare Conference
-
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights
-
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights
-
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018
-
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018
-
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
-
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
-
OptiNose (OPTN) Reports Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
-
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
-
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
-
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
-
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
-
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights

